In summary, our studies have demonstrated that sequential administrations of paclitaxel followed by gefitinib result in the most effective cytotoxic effects in NSCLC cell lines harboring EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.